2:52 PM
 | 
Jul 12, 2018
 |  BC Extra  |  Company News

Korea: Samsung Biologics violated accounting rules

Korea’s Securities and Futures Commission ruled Thursday that Samsung BioLogics Co. Ltd. (KSE:207940) violated accounting rules during its 2016 IPO and has requested dismissal of executives and referral of the case to...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >